This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Interventions for cognitive symptoms in dementia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

nterventions for cognitive symptoms

Non pharmacological intervention

  • "structured group cognitive stimulation therapy" have been shown to be beneficial for people with mild to moderate dementia. Cognitive stimulation include:
    • exposure to and engagement of activities and materials involving some degree of cognitive processing which are usually within a social context (1)
    • often these are group based, with the importance on enjoyment of activities (1)
    • activities include
      • a programme of memory provoking, problem solving and conversational activities
      • the space retrieval method
      • face name training (2)
    • should be considered irrespective of drug treatment (1)
    • can be done at home by a caregiver and requires minimal training or education of the care giver (2)
  • reality orientation therapy (ROT) is a psychosocial intervention used on an individualised basis and has proven to be useful for people who are disoriented in time, place and person (2)

Pharmacological therapy

Pharmacological treatment of Alzheimer's disease is described in the linked item.

Pharmacological management of non-Alzheimer's dementia

  • donepezil or rivastigmine should be offered to people with mild to moderate dementia with Lewy bodies

  • only consider galantamine for people with mild to moderate dementia with Lewy bodies if donepezil and rivastigmine are not tolerated

  • donepezil or rivastigmine should be considered for people with severe dementia with Lewy bodies

  • consider memantine for people with dementia with Lewy bodies if AChE inhibitors are not tolerated or are contraindicated

  • only consider AChE inhibitors or memantine for people with vascular dementia if they have suspected comorbid Alzheimer's disease, Parkinson's disease dementia or dementia with Lewy bodies

  • do not offer AChE inhibitors or memantine to people with frontotemporal dementia

  • do not offer AChE inhibitors or memantine to people with cognitive impairment caused by multiple sclerosis

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.